# Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

*PRI Rank #11 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-11*

| Field | Value |
| --- | --- |
| Rank | #11 |
| 18m citations | 57 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.24.00144 |
| Corresponding authors | Yen-Shen Lu |
| Institution | National Taiwan University Hospital, Taiwan |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1200/jco.24.00144](https://doi.org/10.1200/jco.24.00144)

## Topics

ribociclib · CDK4/6 inhibitor · endocrine therapy · combination chemotherapy · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · premenopausal women · clinically aggressive disease · letrozole · anastrozole · goserelin · docetaxel plus capecitabine · paclitaxel plus gemcitabine · capecitabine plus vinorelbine · visceral disease · visceral crisis · progression-free survival · Overall response rate · time to response

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```